Nexalin Technology Neurostimulation Device Shows Significant ADHD Symptom Improvement in Clinical Study
I'm PortAI, I can summarize articles.
Nexalin Technology Inc. announced a peer-reviewed clinical study published in Molecular Psychiatry, demonstrating that its Deep Intracranial Frequency Stimulation (DIFS™) technology significantly improves ADHD symptoms in adults. The study revealed that four weeks of non-invasive DIFS™ neurostimulation led to notable enhancements in attention, mood, and sleep quality, supported by objective brain activity changes measured by EEG and MEG. The treatment was well tolerated, with a safety profile similar to sham stimulation and no serious adverse events reported.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments